CmaxInsight’s “Peripheral T-Cell Lymphomas (PTCL)-Epidemiology Forecasting Intelligence” report provides a comprehensive analysis of the Peripheral T-Cell Lymphomas (PTCL) epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.
Our epidemiology services include:
• Incidence and prevalence
• Diagnosis rate, treatment rate and mortality patterns
• Epidemiology-based forecasting and disease trends
• Size of different patient segments in a disease area
• Population based: disease occurrence, co-morbidities and treatment patterns
• Geographic - Regional - Ethnic differences
Along with the epidemiological data, the report also includes:
• Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment
• Patient treatment journey
• Treatment algorithm and guidelines
• Assesses the disease risk and burden
• Highlights the unmet needs
• Market driver and barrier
• Growth opportunities and market trend analysis
Methodology
• This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.
• To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.
• All of the sources used to generate the data and analysis have been identified in the report.
Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Interested in this report?
Get your sample now!
1. Report Introduction
2. Peripheral T-Cell Lymphomas (PTCL) Epidemiology Overview at a Glance
3. Market Share Distribution of Peripheral T-Cell Lymphomas (PTCL)
4. Disease Background and Overview: Peripheral T-Cell Lymphomas (PTCL)
4.1. Introduction
4.2. Signs and Symptoms
4.3. Etiology
4.4. Risk Factors
4.5. Pathophysiology
4.6. Diagnostic Landscape
4.6.1. Diagnostic Practices
4.6.2. Diagnostic Criteria
4.6.3. Diagnostic Recommendations
4.7. Treatment Landscape
4.7.1. Current Treatment Practices
4.7.2. Treatment Algorithm
4.7.3. Treatment Recommendations
5. Peripheral T-Cell Lymphomas (PTCL) Epidemiology
5.1. Key Findings
5.2. Assumptions & Rationale
5.3. 7MM Epidemiology
6. Epidemiology of Peripheral T-Cell Lymphomas (PTCL) by Countries
7. United States
7.1. Assumptions and Rationale
7.2. Prevalent/Incident Cases of Peripheral T-Cell Lymphomas (PTCL)
7.3. Sub-Type Specific cases of Peripheral T-Cell Lymphomas (PTCL)*
7.4. Sex- Specific Cases of Peripheral T-Cell Lymphomas (PTCL)*
7.5. Diagnosed Cases of Peripheral T-Cell Lymphomas (PTCL)
7.6. Treated Cases of Peripheral T-Cell Lymphomas (PTCL)
8. EU5
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent/Incident Cases of Peripheral T-Cell Lymphomas (PTCL)
8.1.3. Sub-Type Specific cases of Peripheral T-Cell Lymphomas (PTCL)*
8.1.4. Sex- Specific Cases of Peripheral T-Cell Lymphomas (PTCL)*
8.1.5. Diagnosed Cases of Peripheral T-Cell Lymphomas (PTCL)
8.1.6. Treated Cases of Peripheral T-Cell Lymphomas (PTCL)
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent/Incident Cases of Peripheral T-Cell Lymphomas (PTCL)
8.2.3. Sub-Type Specific cases of Peripheral T-Cell Lymphomas (PTCL)*
8.2.4. Sex- Specific Cases of Peripheral T-Cell Lymphomas (PTCL)*
8.2.5. Diagnosed Cases of Peripheral T-Cell Lymphomas (PTCL)
8.2.6. Treated Cases of Peripheral T-Cell Lymphomas (PTCL)
8.3. United Kingdom
8.3.1. Assumptions and Rationale
8.3.2. Prevalent/Incident Cases of Peripheral T-Cell Lymphomas (PTCL)
8.3.3. Sub-Type Specific cases of Peripheral T-Cell Lymphomas (PTCL)*
8.3.4. Sex- Specific Cases of Peripheral T-Cell Lymphomas (PTCL)*
8.3.5. Diagnosed Cases of Peripheral T-Cell Lymphomas (PTCL)
8.3.6. Treated Cases of Peripheral T-Cell Lymphomas (PTCL)
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent/Incident Cases of Peripheral T-Cell Lymphomas (PTCL)
8.4.3. Sub-Type Specific cases of Peripheral T-Cell Lymphomas (PTCL)*
8.4.4. Sex- Specific Cases of Peripheral T-Cell Lymphomas (PTCL)*
8.4.5. Diagnosed Cases of Peripheral T-Cell Lymphomas (PTCL)
8.4.6. Treated Cases of Peripheral T-Cell Lymphomas (PTCL)
8.5. Italy
8.5.1. Assumptions and Rationale
8.5.2. Prevalent/Incident Cases of Peripheral T-Cell Lymphomas (PTCL)
8.5.3. Sub-Type Specific cases of Peripheral T-Cell Lymphomas (PTCL)*
8.5.4. Sex- Specific Cases of Peripheral T-Cell Lymphomas (PTCL)*
8.5.5. Diagnosed Cases of Peripheral T-Cell Lymphomas (PTCL)
8.5.6. Treated Cases of Peripheral T-Cell Lymphomas (PTCL)
9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent/Incident Cases of Peripheral T-Cell Lymphomas (PTCL)
9.3. Sub-Type Specific cases of Peripheral T-Cell Lymphomas (PTCL)*
9.4. Sex- Specific Cases of Peripheral T-Cell Lymphomas (PTCL)*
9.5. Diagnosed Cases of Peripheral T-Cell Lymphomas (PTCL)
9.6. Treated Cases of Peripheral T-Cell Lymphomas (PTCL)
10. Unmet Needs
Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.
Table 1: Total Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in 7MM
Table 2: Total Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in United States
Table 4: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in United States*
Table 5: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in United States*
Table 6: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in United States
Table 7: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in United States
Table 8: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in Germany
Table 9: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Germany*
Table 10: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Germany*
Table 11: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in Germany
Table 12: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in Germany
Table 13: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in France
Table 14: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in France*
Table 15: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in France*
Table 16: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in France
Table 17: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in France
Table 18: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in Italy
Table 19: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Italy*
Table 20: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Italy*
Table 21: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in Italy
Table 22: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in Italy
Table 23: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in Spain
Table 24: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Spain*
Table 25: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Spain*
Table 26: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in Spain
Table 27: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in Spain
Table 28: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in UK
Table 29: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in UK*
Table 30: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in UK*
Table 31: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in UK
Table 32: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in UK
Table 33: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in Japan
Table 34: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Japan*
Table 35: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Japan*
Table 36: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in Japan
Table 37: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in Japan
*Indication Specific
Figure 1: Total Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in United States
Figure 4: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in United States*
Figure 5: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in United States*
Figure 6: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in United States
Figure 7: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in United States
Figure 8: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in Germany
Figure 9: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Germany*
Figure 10: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Germany*
Figure 11: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in Germany
Figure 12: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in Germany
Figure 13: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in France
Figure 14: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in France*
Figure 15: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in France*
Figure 16: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in France
Figure 17: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in United France
Figure 18: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in Italy
Figure 19: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Italy*
Figure 20: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Italy*
Figure 21: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in Italy
Figure 22: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in Italy
Figure 23: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in Spain
Figure 24: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Spain*
Figure 25: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Spain*
Figure 26: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in Spain
Figure 27: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in Spain
Figure 28: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in UK
Figure 29: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in UK*
Figure 30: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in UK*
Figure 31: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in UK
Figure 32: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in UK
Figure 33: Prevalent/Incident Cases of the Peripheral T-Cell Lymphomas (PTCL) in Japan
Figure 34: Sub-Type Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Japan*
Figure 35: Sex- Specific Cases of the Peripheral T-Cell Lymphomas (PTCL) in Japan*
Figure 36: Diagnosed Cases of the Peripheral T-Cell Lymphomas (PTCL) in Japan
Figure 37: Treated Cases of the Peripheral T-Cell Lymphomas (PTCL) in Japan
*Indication Specific
